JP2014511691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511691A5 JP2014511691A5 JP2014503245A JP2014503245A JP2014511691A5 JP 2014511691 A5 JP2014511691 A5 JP 2014511691A5 JP 2014503245 A JP2014503245 A JP 2014503245A JP 2014503245 A JP2014503245 A JP 2014503245A JP 2014511691 A5 JP2014511691 A5 JP 2014511691A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- wild
- nucleotides
- replaced
- index
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002773 nucleotide Substances 0.000 claims description 497
- 125000003729 nucleotide group Chemical group 0.000 claims description 497
- 208000005980 beta thalassemia Diseases 0.000 claims description 140
- 238000000034 method Methods 0.000 claims description 80
- 230000008859 change Effects 0.000 claims description 65
- 108700028369 Alleles Proteins 0.000 claims description 62
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 57
- 150000007523 nucleic acids Chemical class 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 238000004458 analytical method Methods 0.000 claims description 37
- 108091034117 Oligonucleotide Proteins 0.000 claims description 28
- 238000001514 detection method Methods 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 12
- 108010033040 Histones Proteins 0.000 claims description 11
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 9
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 9
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 238000003205 genotyping method Methods 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 108090000652 Flap endonucleases Proteins 0.000 claims description 5
- 102000004150 Flap endonucleases Human genes 0.000 claims description 5
- 108090000364 Ligases Proteins 0.000 claims description 5
- 102000003960 Ligases Human genes 0.000 claims description 5
- 238000005251 capillar electrophoresis Methods 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000001155 isoelectric focusing Methods 0.000 claims description 5
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 210000002105 tongue Anatomy 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 238000012300 Sequence Analysis Methods 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 210000005067 joint tissue Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 80
- 108020004414 DNA Proteins 0.000 description 39
- 210000000349 chromosome Anatomy 0.000 description 35
- 230000000295 complement effect Effects 0.000 description 25
- 230000035772 mutation Effects 0.000 description 24
- 102000054766 genetic haplotypes Human genes 0.000 description 21
- 239000003446 ligand Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 238000003908 quality control method Methods 0.000 description 16
- 208000007502 anemia Diseases 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 208000002903 Thalassemia Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 10
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 206010043391 Thalassaemia beta Diseases 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000035203 thalassemia minor Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010027616 Hemoglobin A2 Proteins 0.000 description 5
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010085682 Hemoglobin A Proteins 0.000 description 4
- 102000007513 Hemoglobin A Human genes 0.000 description 4
- 201000006288 alpha thalassemia Diseases 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009223 counseling Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000022809 beta-thalassemia intermedia Diseases 0.000 description 3
- 208000022806 beta-thalassemia major Diseases 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000012070 whole genome sequencing analysis Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 101150013707 HBB gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 208000010555 moderate anemia Diseases 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- 101100271206 Arabidopsis thaliana ATHB-15 gene Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101001107784 Caenorhabditis elegans Deoxyribonuclease-2 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010043939 Ephrin-A5 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010068308 Hemoglobin H Proteins 0.000 description 1
- 101710177112 Hemoglobin subunit alpha-1 Proteins 0.000 description 1
- 101000910782 Homo sapiens Carboxypeptidase A6 Proteins 0.000 description 1
- 101000749883 Homo sapiens Contactin-associated protein-like 5 Proteins 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 101001017592 Homo sapiens Mediator of RNA polymerase II transcription subunit 13-like Proteins 0.000 description 1
- 101000632657 Homo sapiens NAD-capped RNA hydrolase NUDT12 Proteins 0.000 description 1
- 101100352903 Homo sapiens PPP3CA gene Proteins 0.000 description 1
- 101001067178 Homo sapiens Plexin-A4 Proteins 0.000 description 1
- 101000974710 Homo sapiens Potassium voltage-gated channel subfamily E member 4 Proteins 0.000 description 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
- 101000793150 Homo sapiens Putative uncharacterized protein encoded by LINC00173 Proteins 0.000 description 1
- 101000742854 Homo sapiens Roquin-1 Proteins 0.000 description 1
- 101000873676 Homo sapiens Secretogranin-2 Proteins 0.000 description 1
- 101000626577 Homo sapiens Transmembrane protein 178A Proteins 0.000 description 1
- 108010000178 IGF-I-IGFBP-3 complex Proteins 0.000 description 1
- 102100030550 Menin Human genes 0.000 description 1
- 208000036696 Microcytic anaemia Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 102100030974 Putative uncharacterized protein encoded by LINC00173 Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000034153 Thalassaemia trait Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000003391 densitometric scan Methods 0.000 description 1
- 108010002712 deoxyribonuclease II Proteins 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007671 third-generation sequencing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472228P | 2011-04-06 | 2011-04-06 | |
| US61/472,228 | 2011-04-06 | ||
| PCT/IB2012/051520 WO2012137110A1 (en) | 2011-04-06 | 2012-03-29 | Association markers for beta thalassemia trait |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511691A JP2014511691A (ja) | 2014-05-19 |
| JP2014511691A5 true JP2014511691A5 (enExample) | 2015-09-03 |
Family
ID=45937505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503245A Withdrawn JP2014511691A (ja) | 2011-04-06 | 2012-03-29 | ベータセラセミア形質新規関連マーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140148344A1 (enExample) |
| EP (1) | EP2694674A1 (enExample) |
| JP (1) | JP2014511691A (enExample) |
| CN (1) | CN103649332A (enExample) |
| BR (1) | BR112013025492A2 (enExample) |
| RU (1) | RU2013149142A (enExample) |
| WO (1) | WO2012137110A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6598450B2 (ja) * | 2014-10-28 | 2019-10-30 | 花王株式会社 | 皮膚性状判定のための遺伝子検出方法 |
| CN109300545B (zh) * | 2018-08-28 | 2021-06-18 | 昆明理工大学 | 一种基于rf的地中海贫血病的风险预警方法 |
| CN109346182B (zh) * | 2018-08-28 | 2021-06-18 | 昆明理工大学 | 一种基于cs-rf的地中海贫血病的风险预警方法 |
| CN111638261B (zh) * | 2020-04-17 | 2023-04-07 | 融智生物科技（青岛）有限公司 | 一种计算设备、存储介质和地中海贫血筛查装置及系统 |
| CN112708668B (zh) * | 2021-01-19 | 2022-10-18 | 中南大学 | Hsp70作为检测地中海贫血的分子标记物及其在制备诊断试剂盒中的应用 |
| CN115948531A (zh) * | 2022-08-09 | 2023-04-11 | 杭州金诺医学检验实验室有限公司 | 一种检测非缺失型地贫的引物组、方法及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018178A1 (en) * | 1992-03-13 | 1993-09-16 | The Children's Hospital Of Philadelphia | DIAGNOSIS OF β-THALASSEMIA USING A MULTIPLEX AMPLIFICATION REFRACTORY MUTATION SYSTEM |
| ITRM20040081A1 (it) * | 2004-02-13 | 2004-05-13 | Biochemical Systems Internat | Sonde oligonucleotidiche per la diagnosi delle diverse forme di beta-talassemia e relativi metodi e kit diagnostici. |
-
2012
- 2012-03-29 CN CN201280016846.3A patent/CN103649332A/zh active Pending
- 2012-03-29 WO PCT/IB2012/051520 patent/WO2012137110A1/en not_active Ceased
- 2012-03-29 RU RU2013149142/10A patent/RU2013149142A/ru not_active Application Discontinuation
- 2012-03-29 EP EP12713376.7A patent/EP2694674A1/en not_active Withdrawn
- 2012-03-29 JP JP2014503245A patent/JP2014511691A/ja not_active Withdrawn
- 2012-03-29 US US14/007,673 patent/US20140148344A1/en not_active Abandoned
- 2012-03-29 BR BR112013025492A patent/BR112013025492A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6203217B2 (ja) | 緑内障進行リスクの判定方法 | |
| JP6830094B2 (ja) | 染色体異常を検出するための核酸及び方法 | |
| EP2851432B1 (en) | RCA locus analysis to assess susceptibility to AMD | |
| US20150322518A1 (en) | Biomarkers for autism spectrum disorders | |
| CN108779487A (zh) | 用于检测甲基化状态的核酸和方法 | |
| CN102206701B (zh) | 遗传性疾病相关基因的鉴定方法 | |
| JP4515524B2 (ja) | 正常眼圧緑内障疾患感受性遺伝子及びその利用 | |
| JP2014511691A5 (enExample) | ||
| JP2014511691A (ja) | ベータセラセミア形質新規関連マーカー | |
| RU2458131C1 (ru) | Тест-система для определения мутаций в генах фумарилацетоацетат гидролазы и альфа-1-антитрипсина человека | |
| JP5043985B2 (ja) | 正常眼圧緑内障疾患感受性遺伝子及びその利用 | |
| KR102095017B1 (ko) | Col6a6 유전자 단일염기다형성을 이용한 아토피 피부염 진단용 조성물과 검출 방법 | |
| WO2012173809A2 (en) | Method of identifying de novo copy number variants (cnv) using mz twins discordant for attention problems/disorders | |
| EP2707497B1 (en) | Detecting the brachyspina mutation | |
| JP5809388B2 (ja) | スティーブンス・ジョンソン症候群の発症リスクの判定方法 | |
| WO2013103094A1 (ja) | コフィン－シリス症候群の検出方法 | |
| EP2149612A1 (en) | Genetic markers of response to efalizumab | |
| WO2009036513A1 (en) | Diagnostic and therapeutic protocols | |
| AU2013203231A1 (en) | RCA locus analysis to assess susceptibility to AMD and MPGNII |